Cargando…
Clinical Outcomes and Selection Criteria for Prodromal Huntington's Disease Trials
BACKGROUND: Huntington's disease (HD) develops in individuals with extended cytosine‐adenine‐guanine (CAG) repeats within the huntingtin (HTT) gene, causing neurodegeneration and progressive motor and cognitive symptoms. The inclusion of mutant HTT carriers in whom overt symptoms are not yet fu...
Autores principales: | Langbehn, Douglas R., Hersch, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818458/ https://www.ncbi.nlm.nih.gov/pubmed/32686867 http://dx.doi.org/10.1002/mds.28222 |
Ejemplares similares
-
Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial
por: Langbehn, Douglas R., et al.
Publicado: (2022) -
Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children
por: Byrne, Lauren M., et al.
Publicado: (2022) -
Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy
por: Arnaldi, Dario, et al.
Publicado: (2021) -
Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population‐Based 10‐Year Study
por: Marini, Kathrin, et al.
Publicado: (2021) -
Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
por: Dommershuijsen, Lisanne J., et al.
Publicado: (2020)